Skip to main content

Table 1 Data and metrics included in the chronic kidney disease registry

From: Development of an electronic health record-based chronic kidney disease registry to promote population health management

  Definition (if applicable) Categorization (if applicable)
Patient Characteristics
 Race   White; African-American; Hispanic; Other
 Comorbidities   Diabetes; HTN; CHF; CVD; COPD; Asthma; Obesity
 Insurance   Medicare; Medicaid; Commercial; Other; Unknown
 PCP   Name, last date of visit
 Nephrologist   Name, last date of visit
Disease Characteristics
 CKD stage   Stages 3A, 3B, 4, 5, 5D
 Kidney failure risk score 2- and 5- year risk of progression to ESRDa 2-year, 5-year risk of progression
 Rate of eGFR change % change in eGFR by at least 90 days  
Laboratory Data
 Serum creatinine   Continuous by mg/dl
 eGFRb   Continuous by ml/min/1.73 m2
 ED Visits, n/per year   
 Inpatient Visits, n/per year   
 Outpatient PCP Visits, n/per year   
 Outpatient Nephrology Visits, n/per year   
 Annual creatinine   Yes or no, date obtained, value
 Annual urine protein testing   Yes or no, date obtained, value
 Blood pressure control   Yes, no, or unknown
 ACE-I/ARB use   Yes, no, or not applicablec
 Nephrotoxin status Review of patient electronic medication list for presence of any one of several medications thought to be unsafe in patients with CKD, based on KDIGO guidelines and CKD collaborative consensus 1. Prescribed no renally unsafe medications
2. Prescribed potentially unsafe medications
3. Prescribed renally unsafe medication (eGFR ≤30)
 Hepatitis B immunity status   1. Immune by HbsAb
2. Immunization received
3. Not immune by HBsAb
 Patient reported outcome measures (PROMs)   Completed, not completed, scores
 Placement of AVF/AVGd   Yes, no
 Transplant statuse   1. None
2. Referral
3. Evaluation
4. Waitlist
5. Transplanted
  1. Abbreviations: EHR Electronic health record, HTN Hypertension, CHF Congestive heart failure, CVD Cardiovascular disease, including coronary artery disease, peripheral vascular disease and stroke, COPD Chronic obstructive pulmonary disease, PCP Primary care provider, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blocker, AVF Arteriovenous fistula, AVG Arteriovenous graft
  2. aBased on Tangri et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA 2016
  3. Patients included based on presence of eGFR and urine protein quantification separated by less than or equal to 1 year (total of 5487 patients)
  4. bPrior to March 2018, the EHR calculated eGFR using the Modification of Diet in Renal Disease (MDRD) equation; subsequently, the EHR has utilized the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) serum creatinine equation; adjusted for African American race by multiplying generic eGFR values by 1.212
  5. c“not applicable” if patient did not have hypertension, diabetes, or proteinuria, or if they did have last serum potassium > 5.0 meq/L, bilateral renal artery stenosis, documented nephrotoxic reaction to ACE-I/ARB, documented angioedema or swelling reaction to ACE-I/ARB, or were pregnant
  6. dPresence of a CPT code, ICD-10 or dialysis access documentation field within EHR for AVF and/or AVG
  7. ePresence of “transplant status” field within EHR